DexCom Study Demonstrates CGM Benefits in Type 2 Diabetes

Results from DexCom Inc.’s CONNECT trial show that Dexcom G7 significantly reduces A1C and improves glucose control in people with Type 2 diabetes who do not use insulin, compared with routine care using self-monitoring of blood glucose.¹

“The CONNECT study is the first and only level A evidence demonstrating strong benefit of CGM for the Type 2 non-insulin-using population,” said Roy Beck, M.D., Ph.D., medical director of the JAEB Center for Health Research and senior study author. “Level A evidence, the highest level of evidence graded by the ADA, has historically driven meaningful changes in standards of care.”

The randomized controlled CONNECT trial demonstrated clinically significant benefit for all adult Type 2 non-insulin-using patients regardless of age, gender, ethnicity, baseline A1C, body mass index, education level, income, and insurance coverage.¹ The study also showed an additional clinically significant reduction in A1C when using Dexcom G7 with various combinations of current care standards in diabetes medication, including metformin, GLP-1s and SGLT2s.¹

“We anticipate these results will help establish a new standard of care in the U.S. and around the world,” DexCom President/CEO Jake Leach stated. “This is the third Dexcom-sponsored randomized controlled trial that has, or will drive, Dexcom CGM to be the standard of care in people with Type 2 diabetes.”

All CONNECT study participants were provided diabetes education on diet and exercise at the study’s start, given a blood glucose meter, and pre-study glucose-lowering medications were continued. Half of the study participants were put on Dexcom G7, and half of them self-monitored their blood glucose. The CONNECT study initially screened 440 participants across 22 primary care U.S. practices, of which 283 eligible participants were randomized to Dexcom G7 or routine care, with 265 completing the 26-week study and analyzed for the key outcomes.

Key outcomes from the study include:¹

• Average 1.6% A1C reduction with Dexcom G7 from baseline mean A1C of 8.8%.
  • Participants using Dexcom G7 experienced on average a 1.6% A1C reduction at 26 weeks, representing a 0.9% greater A1C reduction compared to the control group.
  • Participants using Dexcom G7 with an initial A1C >10% experienced on average a 3.1% A1C reduction, representing a 2.1% greater A1C reduction compared to the control group.
  • 82% of participants had a clinically and statistically significant lower A1C of at least 0.5%.
    
• 68% of participants using Dexcom G7 reached <7.5% A1C at 26 weeks and 46% reached < 7.0% A1C at 26 weeks, demonstrating both clinically and statistically significant reductions.
• The use of Dexcom G7 alone lowered A1C more than any other medication treatment group with a 2.4% reduction in A1c compared to 1.5% in the control group.
• The use of Dexcom G7 had an additive effect in lowering A1C across all medication groups.
  • In participants using GLP-1s, using Dexcom G7 resulted in a 1.4% reduction in A1C compared to 0.2% in the control group.
  • In participants using SGLT2s, using Dexcom G7 resulted in a 1.8% reduction in A1C compared to 0.7% in the control group.
    
• Time in the glucose target range of 70 to 180 mg/dL was five hours per day greater for participants using Dexcom G7 compared to the control group.
  • Those using Dexcom G7 observed overall a clinically significant time in range improvement as early as one to four weeks and sustained it through 26 weeks.
  • On average at the end of 26 weeks, participants using Dexcom G7 achieved 62% time in range compared to 41% in the control group.
    
• Participants using Dexcom G7 reported a greater satisfaction with the use of Dexcom CGM compared to those using self-monitoring of blood glucose and reduced diabetes distress and disease burden.
  • There was a median Dexcom G7 daily usage of 97% throughout the 26-week study.

A six-month extension phase of the CONNECT randomized controlled trial is currently being conducted, which will provide further data on Dexcom G7’s sustainable benefits up to 12 months.

The CONNECT study is of similar magnitude to previous randomized controlled trials, such as JDRF, DIAMOND, and MOBILE, which demonstrated the benefits of CGM use among insulin-using people with diabetes and helped define CGM as the care standard for people with Type 1 and Type 2 diabetes on intensive and basal insulin.

DexCom empowers people to take control of health through biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed the way people manage diabetes and track their glucose.

Reference
¹ Oser T, et al. CGM for Adults with Type 2 Diabetes Not on Insulin: The CONNECT Randomized Controlled Trial. Presented at the 2026 Scientific Sessions of the American Diabetes Association, June 6, 2026. New Orleans, LA; USA.